Objective: This study aimed to determine the efficacy and tolerability of apatinib plus dose-dense temozolomide (TMZ) as first-line treatment for recurrent glioblastoma (rGBM).
Methods: Patients with rGBM were enrolled in this study. Patients were subjected to concurrent treatment of apatinib (500 mg qd) and dose-dense TMZ (100 mg/m2, 7 days on with 7 days off) until disease progression or intolerable toxicity. Efficacy was evaluated using Response Assessment in Neuro-Oncology criteria for high-grade glioma. Safety was assessed using NCI-CTCAE 4.0. Survival was estimated with Kaplan-Meier curve and log rank test.
Results: From March 2016 to January 2018, 20 eligible patients who had relapsed from the standard chemoradiotherapy regimen (TMZ and radiotherapy) were enrolled in this study. The median follow-up time was 12 months. All patients were eligible for efficacy analysis. The objective response rate (ORR) was 45%. The disease control rate (DCR) was 90%. The median progress-free survival time was 6 months (95% CI, 5.3 to 7.8 months). The 6-month progression-free survival rate was 50%. The median overall survival was 9 months (95% CI, 8.2 to 12.2 months). The most common treatment-related adverse events were hypertension (21%), hand-foot syndrome (16%), leukopenia (14%), and thrombocytopenia (12%).
Conclusion: Apatinib combined with dose-dense TMZ was effective in terms of PFS, ORR, and DCR and was well tolerated after appropriate dose reduction in the Chinese population tested. Further randomized controlled clinical studies are needed to confirm the efficacy of apatinib combined with TMZ for treatment of rGBM.
Keywords: apatinib; central nervous system; glioblastoma; recurrence; temozolomide; vascular endothelial growth factor receptor.
© 2019 Wang et al.
Conflict of interest statement
The authors declare that they have no competing interests.
A Phase II Study of Apatinib in Patients With Recurrent Epithelial Ovarian CancerM Miao et al. Gynecol Oncol 148 (2), 286-290. PMID 29248198. - Clinical TrialApatinib 500mg daily p.o. is a feasible treatment in patients with recurrent, platinum-resistant, pretreated EOC. Multi-center prospective studies enrolling more patients …
A Multicenter Phase II Study of Temozolomide Plus Disulfiram and Copper for Recurrent Temozolomide-Resistant GlioblastomaJ Huang et al. J Neurooncol 142 (3), 537-544. PMID 30771200. - Clinical TrialAddition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population.
Efficacy and Safety of Apatinib in Patients With Advanced Nonsmall Cell Lung Cancer That Failed Prior Chemotherapy or EGFR-TKIs: A Pooled AnalysisJT Ma et al. Medicine (Baltimore) 97 (35), e12083. PMID 30170427.Apatinib has promising antitumor activity and manageable toxicity profile in patients with advanced NSCLC that failed prior chemotherapy or EGFR-TKIs. This result needs t …
Procarbazine, Lomustine and Vincristine for Recurrent High-Grade GliomaS Parasramka et al. Cochrane Database Syst Rev 7 (7), CD011773. PMID 28744879. - ReviewEvidence is based on a single large trial analysis as the other trial was small, with inadequate power to detect survival difference. Chemotherapy-naive patients with HGG …
The Safety of Apatinib for the Treatment of Gastric CancerR Geng et al. Expert Opin Drug Saf 17 (11), 1145-1150. PMID 30324820. - ReviewApatinib is an orally administered small-molecule vascular endothelial growth factor receptor 2 inhibitor. It has been approved and indicated for advanced gastric cancer …